TapImmune Inc. — Form 10-Q Summary
Filing identity: The supplied filing is for TapImmune Inc., not Marker Therapeutics, Inc. It covers the quarter and nine months ended September 30, 2012; financial statements are unaudited. The company described itself as a development-stage biotechnology company.
Business context and reporting period
TapImmune was developing TAP-based immunotherapies and vaccines, with programs in HER2/neu-positive breast cancer and infectious diseases. The filing says patient dosing had begun in a Mayo Clinic Phase I HER2/neu vaccine trial, with an interim safety review planned. The company reported no revenue in the periods discussed.
Key financial metrics
| Metric | Reported result |
|---|---|
| Revenue | None reported for the three- and nine-month periods. |
| Net loss, three months | $768,095 in 2012 versus $844,277 in 2011, per the financial statements; loss per share was $0.01 versus $0.02. |
| Net loss, nine months | $4,118,684 in 2012 versus $2,378,036 in 2011; loss per share was $0.07 versus $0.05. |
| Operating costs, three months | $905,000 in 2012 versus $797,000 in 2011, as rounded in MD&A. |
| Operating costs, nine months | $4,609,000 in 2012 versus $2,707,000 in 2011, as rounded in MD&A. |
| Cash and total assets | Cash was $3,727 and total assets were $60,739 at September 30, 2012, versus cash of $250,234 and total assets of $340,212 at December 31, 2011. |
| Cash flow, nine months | $1,116,770 used in operating activities; $870,263 provided by financing activities; cash decreased by $246,507. |
| Liabilities and equity | Current liabilities totaled $4,428,280. Convertible notes payable were $1,184,351; warrant and conversion-option derivative liabilities totaled $1,072,558. Stockholders’ deficit was $4,367,541. |
Margins are not meaningful for this pre-revenue company. The filing gives two different working-capital-deficit figures excluding derivative liabilities: $3,315,751 in Note 1 and $3,323,251 in MD&A. The filing does not provide a clear reconciled value.
Material changes versus the prior comparable period
- Nine-month net loss increased to $4.12 million from $2.38 million. Stock-based consulting expense rose to $2.28 million from $692,253, and general and administrative expense rose to $880,353 from $66,012.
- Quarterly results improved year over year according to the financial statements, but the MD&A reverses the comparison, stating a $844,000 loss in 2012 versus $768,000 in 2011. Investors should verify the correct period labels and amounts.
- Cash fell sharply from year-end, while current liabilities increased. The company issued 14 million shares to financial consultants and conducted additional equity and debt financings.
Outlook, risks, contingencies and unusual items
- Management anticipated no sales revenue in the next 12 months, though grant funding might be received. It estimated approximately $5 million of financing would be needed over the next 24 months, assuming one Phase I trial.
- Management disclosed substantial doubt about the company’s ability to continue as a going concern. Continued operations depend on raising capital, debt-holder accommodations and/or strategic partnerships; the filing says funding may not be sufficient.
- New convertible notes included discounted or variable-price conversion provisions and warrants, creating potential dilution. A further $340,000 face-value note was entered into after quarter-end on October 15, 2012, for $300,000 received, with original issue discount and legal fees. On November 14, the company exchanged a $100,000 note for three new notes with variable-price conversion terms.
- The company was delinquent on payments under its Crucell license, had accrued $365,970, and faced possible license cancellation. Mayo-related research and licensing commitments, including a stated $841,000 cap for specified trial costs and additional license obligations, were also disclosed.
- The company reported that disclosure controls and internal control over financial reporting were ineffective, citing material weaknesses in oversight, segregation of duties, written procedures and period-end reporting controls.
- Other concerns include unfiled tax returns in certain jurisdictions, possible unquantified penalties and interest, and Level 3 derivative valuations based on significant unobservable assumptions. No legal proceedings were reported.
Most important facts for investors to verify
- Confirm the issuer: the filing names TapImmune Inc., despite the request metadata identifying Marker Therapeutics, Inc.
- Reconcile the conflicting quarterly net-loss comparison and the two working-capital-deficit amounts.
- Check cash runway, funding availability, and the terms and subsequent status of the October and November 2012 debt transactions.
- Verify clinical-trial status, milestones, expected costs and the terms needed to maintain the Crucell and Mayo arrangements.
- Assess potential dilution from outstanding and variable-price convertible instruments, warrants and consulting share agreements.
- Monitor remediation of the disclosed control weaknesses and any tax-compliance assessments.